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Abstract
Leishmaniasis remains as one of the most important neglected diseases in the world and, 
after all these years, its treatment is still a problem, mainly because of the side effects 
caused by the first- and second-line drugs and the indiscriminate treatment, which leads 
to increasing cases of parasite resistance. The search for alternative therapies for the 
treatment of leishmaniasis is extremely important. In this context, the use of natural 
products arises as a promising alternative, combining the empirical knowledge dissemi-
nated in the population with researches that aim to scientifically prove the therapeutic 
effects of plants. Based on this, the use of medicinal plants is considered a desirable and 
accessible tool in the treatment of these diseases and considered by pharmacognosy as 
a valuable source for the development of new drugs and as adjuvant for conventional 
therapies.
Keywords: herbal medicine, Leishmania spp., natural products, visceral leishmaniasis, 
traditional medicine
1. Introduction
Protozoa of the genus Leishmania cause a broad spectrum of diseases collectively called 
Leishmaniasis, which represent a serious public health problem worldwide. Its clinical forms 
vary from cutaneous leishmaniasis (CL), characterized by tegumentary lesions that can heal 
and regress spontaneously, to visceral leishmaniasis (VL), more severe and potentially fatal, 
if not treated [1].
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
VL is an important zoonosis caused by parasites of the Leishmania donovani complex (L. donovani 
in India and Central Africa and L. infantum in America, Middle East, Central Asia, China, and 
the Mediterranean Basin) [2, 3]. It is present in 98 countries but, although widely distributed, 
more than 90% of cases are restricted to India, Bangladesh, Sudan, South Sudan, Ethiopia, and 
Brazil [4, 5]. In the Americas, dogs are considered the main reservoir of the parasites, as well as 
an important link for the maintenance of the infection in the urban environment [6] (Figure 1).
Leishmania species have a complex life cycle, alternating between a permissive insect vector 
and a susceptible vertebrate host [8]. The transmission of the parasite occurs through the 
bite of an infected female sandfly, belonging to the genus Phlebotomus, in the Old World, or 
Lutzomyia, in the New World [9]. Once inside the vertebrate host, the promastigote forms 
inoculated by the insect will be phagocytosed by macrophages, transforming into amasti-
gotes. After extensive multiplication, the amastigotes increase in quantity until the cell rup-
tures, leading to infection of other phagocytic cells, continuing the cycle [10].
Other forms of transmission have already been reported, such as vertical and/or sexual trans-
mission [11], non-vector hematogenous [12, 13], and through other vectors, such as Rhipicephalus 
sanguineus [14], but their role in the maintenance of the disease is not totally clear yet.
In epidemiological terms, the dynamics of disease transmission is very complex and depends 
on several factors, such as the socioeconomic status of the population (poor living conditions, 
malnutrition), climate and environmental changes (which leads to sandfly adaptation and 
spread), host–parasite relationship (immunocompromised individuals, evasion mechanisms 
employed by the parasite), and population mobility (international travels and/or migration 
from non-endemic areas to endemic areas), which means that there may be differences in the 
pattern of disease spread, depending on the place [8, 15–18].
Figure 1. Status of endemicity of visceral leishmaniasis worldwide, 2015. Source: Adapted from WHO (2015) [7].
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2. Therapeutic modalities for VL
2.1. Chemotherapy
Despite its importance for both human and animal health, there are few therapeutic options 
for VL treatment. The bases of therapeutic protocols in humans are the pentavalent antimoni-
als (sodium stibogluconate and meglumine antimoniate), but the need of hospitalization and 
the severe side effects caused by its administration leads to high dropout rates among the 
patients, which contributes for parasite resistance in case of disease relapse. Although widely 
used, the mechanism of action of antimonials is still poorly understood [19, 20].
As a second-line drug, amphotericin B was initially recommended for patients who did not 
respond to the treatment with pentavalent antimonials. It presents high cure rates, efficacy, 
and safety, but, once again, needs prolonged hospitalization, for close monitoring of renal 
functions, and has some adverse effects, such as fever and chills [21, 22].
Miltefosine was the first oral drug used for VL cases, which simplified the treatment in several 
aspects. It was originally designed for breast cancer and other solid tumors, but the gastroin-
testinal side effects limited its use [23, 24]. In vitro and in vivo evidences of the antileishmanial 
activity of miltefosine [25–27] conducted in clinical trials in humans and its release for the 
treatment of human VL in many countries [28–30]. However, it should not be used in preg-
nant women due to its teratogenic effect [23]. Besides that, its indiscriminate use, incomplete 
treatment, and the long half-life of the drug has increased the cases of parasitic resistance, 
which represents a serious concern [31].
Other drugs are commonly used as therapeutic alternatives for VL, such as paromomycin, 
pentamidine, and sitamaquine. However, all have variable side effects or cure rates lower 
than the reference drugs [22, 32–36].
In general, all available drugs have problems related to toxicity and high costs, which hinders 
the treatment of Leishmaniasis, especially in poor and developing countries, where the great 
majority of the cases are concentrated [8]. For this reason, it is of great importance the adop-
tion of strategies for the search and development of new candidate drugs. In this context, we 
emphasize the emergence of phytotherapy as a promising therapeutic alternative, since the 
use of natural products is widely disseminated in the population [37]. Therefore, it is neces-
sary to combine the empirical knowledge with researches, with the aim to scientifically prove 
the therapeutic effects of plants—crude extracts, fractions or isolated substances—against 
Leishmania species, especially the causative agents of VL.
2.2. Phytotherapy
Medicinal plants are defined as those administered to man or animals, by any routes, that exert 
some therapeutical activity [38]. Plants are used as sources of new compounds throughout the his-
tory of mankind and, even today, serve as basis of many products used in the medical routine [39].
The use of medicinal plants has become, especially in developing countries, an alternative 
to traditional health services, both in rural areas, deprived of public health resources, as in 
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urban areas, as an option or as a complement to allopathic medication [40]. This tradition has 
been passed on to the populations in every generation, and is configured as a new science, the 
phytotherapy [41].
In countries with a great diversity of flora, such as Brazil, there is a great potential for the 
rational exploitation of plant resources and for the diffusion of herbal practices. Such prac-
tices are able to generate benefits both in the cultural point of view such as contributions to 
the scientific validation of the use of plant species [42, 43], since many of these are consumed 
without their pharmacological properties are, in fact, known [44].
The scientific community reveals a growing interest in this field, recognizing the true health 
benefit that plants provide [45]. The World Health Organization itself recognizes that the 
solution to combating numerous diseases, especially the so-called “neglected diseases,” lies 
in the traditional knowledge and in the development of new drugs derived from biodiversity 
products [46].
Historically, experiments with the use of plants in medicine with therapeutical and healing 
purposes have been reported, which demonstrates that man began to use plants not only as 
food but also as a therapeutic resource for many diseases. Currently, many plant drugs are 
pointed out and described as viable alternatives in the treatment of many diseases [47], pro-
gressively abandoning empirical use based on experiments, starting for rational use based 
on iatrochemistry [48], based on the evident undesirable effects of some synthetic drugs [49].
Tagboto and Townson [50] describe as challenging the path of validation of the use of natu-
ral drugs and this includes not only the discovery of new drugs, but also the certification of 
products already used, culminating in the preservation of biodiversity. These authors report 
that, due to the widespread use of natural drugs being used, especially in underdeveloped 
countries, there was a need for certification of these products, and that due to these reasons, 
in 2000, the World Health Organization created a demand in order to qualify and regulate 
with scientific bases some medicines whose principles are already known, as well as empirical 
ones, in order to identify new possibilities within pharmacognosy.
3. Alternate therapies—mechanism of action
3.1. Immunomodulation by antileishmanial plant products
The immunological condition of a patient infected with Leishmania represents a determinant 
point for a favorable treatment. In visceral leishmaniasis, the immune system is markedly shaken 
by secondary infections and other opportunistic infections associated with the clinical picture of 
the disease, which emphasizes the need for drugs that not only favor immune recovery but also 
present a leishmanicidal action [51]. The modern medicine has changed the focus regarding the 
treatment of several diseases, such as neoplasms and infectious diseases. Traditionally, the drugs 
were developed to act directly on the microorganisms or neoplastic cells, but now, the main goal 
is to strengthen the body’s defenses. Plants have several secondary metabolites, for example, 
flavonoids, polysaccharides, lactones, alkaloids, diterpenoids, and glycosides that may activate 
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the immunological system [52]. Regarding leishmaniosis treatment, Chouhan et al. [53] describe 
the use of medicinal plants as an alternative for modulating the patient’s immune response as 
an effective device in therapy. A combination of miltefosine and nanoparticles of curcumin dis-
played lymphocyte proliferation and increased the phagocytic capacity of peritoneal macro-
phages. This effect was attributed to curcumin [54]. A substance isolated of Casearia arborea, tricin, 
was able to modulate the respiratory burst, which favors the parasite elimination [55].
Awareness of the importance of modulating the immune system has been a crucial point in 
the prevention and treatment of various diseases, and for this reason, the immunomodulatory 
properties of plants have been extensively explored so that researchers seek not only to affect 
the permanence of the pathogen but also have sought to boost both the patient’s natural and 
adaptive defenses [56, 57]. This fact was observed by Almeida-Souza et al. [58], demonstrating 
a hypothesis that determines compounds obtained by different extraction methods can favor 
the increase of mediators such as nitric oxide (NO), increasing the functions and abilities of 
macrophages in the elimination of amastigote forms.
3.2. Reactive oxygen species generation
Against obligate intracellular parasite, macrophages use various mechanisms of action to con-
trol infection, as the induction of reactive oxygen and nitrogen species. Hydrogen peroxide is 
a major source of hydroxyl radicals and other reactive oxygen species, which macrophages 
produce in greater quantities [59, 60]. Among reactive nitrogen species, nitric oxide (NO) has a 
potent microbicide effect against intracellular parasites, such as Leishmania [61]. NO is a freely 
diffusible gas produced by the activity of inducible NO synthase (iNOS) enzyme by the con-
version of L-arginine to L-citrulline. iNOS is induced by various pro-inflammatory factors such 
as cytokines or endotoxins [62]. In its short life, NO acts directly on pathogens by inhibition of 
proliferation, DNA mutagenesis, disruption of [FeS] clusters, metabolic blockade, and inactiva-
tion of virulence factors or molecules associated with infectious pathogens [63]. The functions 
of NO also include immunostimulatory (pro-inflammatory) effects that together with antimi-
crobial activity contribute to the killing of intracellular Leishmania as previous reported [58].
3.3. Apoptosis-inducing potential
The mechanism of action of leishmanicidal drugs is not well elucidated. It has been reported 
that both conventional drugs and some plants extracts used in the treatment of visceral leish-
maniasis may induce a phenomenon like apoptosis in the parasite. The ethanolic extract of 
seeds and leaves of Azadiracta indica [64] and essentials oils of Artemisia campestris and Artemisia 
herba-alba [65] act as an apoptosis inductor in promastigotes of L. donovani and L. infantum, 
respectively.
4. Plants with antileishmanial properties
The available drugs against leishmaniasis do not always present a satisfactory result and have 
been shown as an expressive challenge for current treatment protocols [66]. Many plants that 
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Plant Part of plant Preparation Species Reference
Withania somnifera Leaves; whole 
plant
Alcoholic fractions F5 and F6; 
tablets; methanolic extract 
(fraction A6)
L. donovani Chandrasekaran et al. [68]
Kaur et al. [73]
Sharma et al. [74]
Inula chritmoides Not cited Acetone and dichloromethane 
extracts
L. infantum Oliveira et al. [75]
Casearia arborea Leaves Methanolic extract L. infantum Santos et al. [55]
Curcuma longa Rhizome Oral formulation based on 
nanoparticles
L. donovani Tiwari et al. [54]
Spergularia rubra Not cited Acetone and dichloromethane 
extracts
L. infantum Oliveira et al. [75]
Ocimum sanctum Leaves Ethanolic extract L. donovani Bhalla et al. [76];
Kaur et al. [73]
Cocos nucifera Husk fiber Aqueous extract L. donovani Bhalla et al. [76]
Sterculia villosa Bark Methanolic extract L. donovani Das et al. [77]
Coccinia grandis Leaves Extract L. donovai Pramanik et al. [78]
Das et al. [79]
Morinda citrifolia Fruits Aqueous extract
Fruit juice
L. chagasi Almeida-Souza et al. [80]
Solanum tuberosum Tuber Sodium bisulphite extraction L. donovani Paik et al. [81]
Paik et al. [82]
Moringa oleifera Flower Ethyl acetate fraction L. donovani Singh et al. [83]
Azadirachta indica Leaves and 
seeds
Ethanolic fraction and ethyl 
acetate fraction
L. donovani Chouhan et al. [84]; 
Dayakar et al. [85]
Croton caudatus Leaves Hexanic extract L. donovani Dey et al. [86]
Artemisia annua Leaves and 
seeds
n-hexane fractions L. donovani Islamuddin et al. [87] 
Islamuddin et al. [88]
Asparagus racemosus Whole plant Tablets L. donovani Kaur et al. [89]
Sachdeva et al. [90]
Syzygium aromaticum Flower Essential oil L. donovani Islamuddin et al. [91]
Croton cajucara Leaves Essential oil L. chagasi Rodrigues et al. [7]
Solanocia mannii Leaves Extract L. donovani Hubert et al. [92]
Solanum torvum Leaves Extract L. donovani Hubert et al. [92]
Coriandrum sativum Seeds Oleoresin L. chagasi Rondon et al. [93]
Lippia sidoides Not cited Essential oil L. chagasi Rondon et al. [93]
Copaifera reticulata Seeds Essential oil L. chagasi Rondon et al. [93]
Spondias mombin Aerial parts Ethanolic extract (Sm3 
fraction)
L. chagasi Accioly et al. [94]
Annona squamosa Leaves Alkaloid and acetogenic 
extract
L. chagasi Vila-Nova et al. [95]
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present anti-infectious characteristics have been studied for the careful detection of new active 
compounds isolated [67] of antiparasitic action and also as immunomodulators, so that they 
are shown as a collection of bioactive compounds for the optimization of the treatment of 
leishmaniasis [68], as well as the presence of active compounds belonging to several chemical 
groups [69–71], such as flavonoids, isoflavonoids, saponins, alkaloids, sesquiterpenes, polysac-
charides, tannins, indoles, and glucans [72].
Much information about plants and formulations employed in popular medicine is contained 
in the literature, and based on this information, new constituents have been successfully per-
fected and clinically tested, correlating traditional and modern medicine, combining science 
and empiricism (Table 1). Traditional medicine is based primarily on personal experience, 
with the use of compounds not yet fully validated, requiring complementary evidence to 
become safe and effective [106].
Plant Part of plant Preparation Species Reference
Annona muricata Seeds Alkaloid and acetogenic 
extract
L. chagasi Vila-Nova et al. [95]
Aloe vera Leaves Extract L. infantum Rondon et al. [96]
Coriandrum sativum Seeds Extract L. infantum Rondon et al. [96]
Ricinus communis Leaves Extract L. infantum Rondon et al. [96]
Valeriana wallichii Root Methanol and chloroform 
extracts
L. donovani Ghosh et al. [97]
Momordica charantia Fruit Crude extract L. donovani Gupta et al. [98]
Kalanchoe pinnata Leaves Aqueous extract L. chagasi Gomes et al. [99]
Allium sativum Bulb Methanolic extract (fraction 
G3)
L. donovani Sharma et al. [74]
Piper betle Leaves Methanolic extract and 
essential oil
L. donovani Misra et al. [100]
Nyctanthes arbor-tristis Leaves Methanolic extract (fraction 
calceolariosidea)
L. donovani Poddar et al. [101]
Aloe vera Leaves Exudate L. donovani Dutta et al. [102]
Tinospora sinensis Powdered 
stem
Ethanolic extract L. donovani Singh et al. [103]
Chenopodium 
ambrosioides
Aerial parts Essential oil L. donovani Manzote et al. [104]
Annona crassiflora Stem bark Exanolic and ethanolic extract L. donovani Mesquita et al. [105]
Himatanthus obovatus Root wood Exanolic and ethanolic extract L. donovani Mesquita et al. [105]
Guarea kunthiana Roots Exanolic and ethanolic extract L. donovani Mesquita et al. [105]
Cupania vernalis Leaves Exanolic and ethanolic extract L. donovani Mesquita et al. [105]
Serjania lethalis Root bark Exanolic and ethanolic extract L. donovani Mesquita et al. [105]
Table 1. Antileishmanial activity of plants against visceral leishmaniasis.




The drugs available for the treatment of visceral leishmaniasis have adverse effects, a high cost, 
and, in addition, parasitic resistance is frequent. These facts are a challenge for modern science, 
which uses traditional medicine as a research source to find a compound that is effective and has 
minimal side effects. Many studies have been carried out, but the results obtained are not very 
encouraging. Most of the plants studied did not present leishmanicidal effect but the immuno-
modulatory effect has often been emphasized. Summarizing, data in the literature show that the 
substances obtained from the study of plants may be excellent allies in the treatment of leishmani-
asis because they have immunomodulatory effects, but none has a direct effect against the parasite.
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